65,437 trials
Endurance Exercise
Primary: Comparison of Blood Lactate Levels During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo. — 0.9699; 1.1437; 1.26345; 1.3618…
Healthy Subjects · Pharmacokinetics · Pharmacodynamics
Primary: Baseline-adjusted Area Under Effect Curve (AUEC) for LDL-C for Evolocumab and Alirocumab — -380; -754; -866; -1832 mg/dL*day
HIV Infections
Primary: Maximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection — 3.38 Microgram per milliliter (ug/mL)
Healthy Subjects · Pharmacokinetics · Pharmacodynamics
Primary: Area Under Effect Curve (AUEC) for Neopterin for Interferon Beta-1a and Peginterferon Beta-1a — 7.82; 9.61; 11.08; 11.52 ng*day/mL
Infant, Newborn · Hypoxia, Brain · Hypoxia-Ischemia, Brain
Primary: Death or Moderate or Severe Disability — 29; 20 Participants
Sexual Abuse
Primary: Number of Participants Who Engage in Mental Health Treatment — 23; 18; 31; 26 Participants
Migraine Headaches
Primary: Migraine Headache Index (MHI) at 1 Year — 7.81; 3.73 index score
Anemia of Chronic Kidney Disease
Primary: Difference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours) — 11.288; -0.259; 20.125; -1.625 gram*3hours/deciliter (g*3hr/dL) — p=0.212
Healthy Subjects · Pharmacokinetics · Pharmacodynamics
Primary: Area Under Effect Curve (AUEC) for Eosinophils for Mepolizumab and Reslizumab — -1804; -195; -1456; -1428 Percentage change from baseline * day
Multiple Myeloma
Primary: Objective Response Rate (ORR)-Unweighted Analysis — 61.0; 31.3; 30.3 Percentage of participants — p=<.0001
Osteoarthritis of the Knee
Primary: Change From Baseline in WOMAC Pain Subscale at Week 12 — -0.83; -0.64; -0.47 score on a scale
Classical Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma · Acute Myeloid Leukemia
Primary: Number of Patients With Dose-limiting Toxicities (DLTs) — 3 Participants
Type1 Diabetes
Primary: Number of Participants That Completed Interviews About Consultation Summaries They Were Receiving — 9 Participants
Leukoplakia, Oral
Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants
Sleep-Related Eating Disorder
Primary: Change in Frequency of Sleep-related Eating Episodes (Time Frame: Comparing Final Study Visit to Baseline) — -41.2; -20.0 change in % of nights eating per week